Waseet Vance
Radiation Oncology · Fleming Island, FLNPI 1477703031
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,287 of the $5,420 with a category attached, or 60.6%. Elekta, Inc. accounts for 64.6% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $3,826, more than ten times the $12 reported in 2019.
Across 71 payments — averaging $76.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elekta, Inc.$4K
- Brainlab, Inc.$566
- GT Medical Technologies, Inc$413
- Novartis$134
- Foundation Medicine, Inc.$89
- Daiichi Sankyo Inc.$80
- plus $636 from 28 others
What the payments were for
- Travel & lodging$3,28761%
- Food & beverage$2,13339%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Elekta, Inc. | 6 | $3,501 |
| Brainlab, Inc. | 6 | $566 |
| GT Medical Technologies, Inc | 3 | $413 |
| Novartis | 10 | $134 |
| Foundation Medicine, Inc. | 1 | $89 |
| Daiichi Sankyo Inc. | 4 | $80 |
| Siemens Medical Solutions USA, Inc. | 4 | $78 |
| Sanofi | 5 | $63 |
| Visionrt, Inc. | 1 | $61 |
| Astellas Pharma US Inc | 3 | $37 |
| Incyte Corporation | 3 | $35 |
| Beigene USA, Inc. | 2 | $29 |
| Octapharma USA, Inc. | 2 | $25 |
| Immunocore Limited | 1 | $24 |
| Accuray Incorporated | 1 | $23 |
| Boehringer Ingelheim | 1 | $21 |
| Clovis Oncology, Inc. | 1 | $20 |
| Merck | 1 | $17 |
| Exelixis Inc. | 1 | $16 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| AbbVie | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Acceleron Pharma, Inc. | 1 | $14 |
| Springworks Therapeutics, Inc. | 1 | $14 |
| CSL Behring | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Aurobindo Pharma USA, Inc. | 1 | $13 |
| Stemline Therapeutics Inc. | 1 | $13 |
| Pfizer | 1 | $12 |
| Genentech USA, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
| Bayer | 1 | $10 |
| United Imaging Healthcare North America, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,420 in reported general payments places this provider in the 80th percentile of 465 radiation oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 20 | $369 |
| Oxycodone Hcl | 16 | $335 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $316 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $184 |
| Famotidine | 19 | $136 |
| Lorazepam | 31 | $28 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Fleming Island
- Shravan KandulaOrlando$444K
- Martin KeischMiami Shores$319K
- Marcio FagundesMiami$274K
- Evan ThomasWinter Park$209K
- Rupesh KotechaMiami$208K
- John SylvesterLakewood Ranch$205K
- Ravi ShridharOrlando$192K
- Alan BrownFort Myers$165K
- Akash NandaOrlando$165K
- Michael ChuongMiami$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.